Oral oncology最新文献

{"title":"Multimodal profiling uncovers tertiary lymphoid structures as a critical determinant of immunotherapy response and prognosis in nasopharyngeal carcinoma.","authors":"Hui Li, Liming Lou, Juan Du, Mei Li, Xianhui Wen, Yuan Zhang, Songran Liu, Zi-Qi Zheng, Xu Liu","doi":"10.1016/j.oraloncology.2024.107129","DOIUrl":"10.1016/j.oraloncology.2024.107129","url":null,"abstract":"<p><p>Nasopharyngeal carcinoma (NPC), historically termed 'lymphoepithelioma-like carcinoma' due to its rich lymphocyte infiltration, benefit from PD-1 blockade treatment. However, a comprehensive understanding of its tumor microenvironment (TME) remains elusive, hindering the identification of effective biomarkers for immunotherapy. We leveraged multimodal profiling data, including gene expression, immunohistochemistry, and multiplex immunohistochemistry, from three independent cohorts of NPC patients with a total of 327 patients to dissect the TME in NPC. Unsupervised hierarchical clustering of TME cell populations in the discovery cohort revealed two novel subtypes with distinct prognosis: 'Immune Inflamed' and 'Immune Deficient'. Intriguingly, the most significant differences between the two subtypes were the abundance of B cells and tertiary lymphoid structures (TLS), with a nearly two-fold increase in TLS presence in the Immune Inflamed subtype. The prognostic significance of TLS was confirmed in three independent NPC cohorts, surpassing the prognostic value of individual immune cell subsets. Mechanistically, TLS enhanced anti-tumor immunity by increasing T and B cell receptor repertoire diversity, promoting infiltration of plasma cells, macrophages, and natural killer cells, and consequently increasing antibody-dependent cell-mediated cytotoxicity and antibody-dependent phagocytosis. Finally, TLS status robustly predicted prognosis in a cohort of NPC patients treated with PD-1 blockade, and its prognostic value was consistent across a pan-cancer immunotherapy cohort of 10 tumors and 1158 patients, although with context-specific effects depending on cancer type and immunotherapy modality. In conclusion, this study provides compelling evidence that TLS is a robust indicator of overall immune response within TME and have great potential to guide individualized immunotherapy.</p>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"107129"},"PeriodicalIF":4.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 10 %-rule debate: A fresh perspective on sentinel lymph node biopsy in OSCC.","authors":"Carlos M Ardila, Pradeep Kumar Yadalam","doi":"10.1016/j.oraloncology.2024.107141","DOIUrl":"10.1016/j.oraloncology.2024.107141","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"107141"},"PeriodicalIF":4.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142838623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering molecular relapse and intra-tumor heterogeneity in non-metastatic resectable head and neck squamous cell carcinoma using circulating tumor DNA","authors":"Grégoire Marret ,&nbsp;Constance Lamy ,&nbsp;Sophie Vacher ,&nbsp;Luc Cabel ,&nbsp;Mathieu Séné ,&nbsp;Ladidi Ahmanache ,&nbsp;Laura Courtois ,&nbsp;Zakhia El Beaino ,&nbsp;Jerzy Klijanienko ,&nbsp;Charlotte Martinat ,&nbsp;Nicolas Servant ,&nbsp;Choumouss Kamoun ,&nbsp;Maral Halladjian ,&nbsp;Thierry Bronzini ,&nbsp;Cédric Balsat ,&nbsp;Jean-François Laes ,&nbsp;Aubray Prévot ,&nbsp;Sébastien Sauvage ,&nbsp;Maxime Lienard ,&nbsp;Emmanuel Martin ,&nbsp;Maud Kamal","doi":"10.1016/j.oraloncology.2024.107111","DOIUrl":"10.1016/j.oraloncology.2024.107111","url":null,"abstract":"<div><h3>Objectives</h3><div>Head and neck squamous cell carcinoma (HNSCC) is characterized by significant genetic intra-tumor heterogeneity (ITH), which may hinder precision medicine strategies that depend on results from single tumor-biopsy specimens. Treatment response assessment relies on radiologic imaging, which cannot detect minimal residual disease (MRD). We assessed the relevance of circulating tumor DNA (ctDNA) as a biomarker for ITH and MRD in HNSCC.</div></div><div><h3>Materials and methods</h3><div>We recruited 41 non-metastatic resectable HNSCC patients treated with upfront curative-intent surgery in the prospective biobanking SCANDARE study (NCT03017573). Thirty-one patients (76 %) showed recurrent disease at a median follow-up of 41 months. Targeted next-generation sequencing was performed on resected tumor tissues, as well as on serial blood samples obtained at surgery, within 14 weeks after surgery, at six months and at recurrence.</div></div><div><h3>Results</h3><div>ctDNA was detected in 21/41 patients at surgery (sensitivity: 51 %; 95 % CI, 35–67 %) and 15/22 patients at recurrence (sensitivity: 68 %; 95 % confidence interval [CI], 45–86 %). Among patients with mutations identified in longitudinal plasma samples, additional mutations missed in tumor tissues were reported in 3/21 patients (14 %), while emerging mutations were reported in 9/21 patients (43 %). In the postoperative surveillance setting, ctDNA-based MRD detection anticipated clinical recurrence with a median lead-time of 9.9 months (interquartile range, 8.0–14.5 months) in 17/27 patients (63 %). When detected within 14 weeks after surgery, MRD correlated with disease recurrence after adjusting for classical prognostic variables (HR = 3.0; 95 % CI, 1.1–7.9; <em>p</em> = 0.03).</div></div><div><h3>Conclusions</h3><div>ctDNA detection is a useful biomarker for ITH and MRD in resectable HNSCC patients.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"Article 107111"},"PeriodicalIF":4.0,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synchronous adenoid cystic carcinoma in the submandibular gland and tongue: A rare case report","authors":"Flávia Sirotheau Corrêa Pontes ,&nbsp;Emilie Christina Teixeira de Barros ,&nbsp;Thaís da Silva Fonseca ,&nbsp;Igor Mesquita Lameira ,&nbsp;Anderson Maurício Paiva e Costa ,&nbsp;Douglas Fabrício da Silva Farias ,&nbsp;Hélder Antônio Rebelo Pontes","doi":"10.1016/j.oraloncology.2024.107128","DOIUrl":"10.1016/j.oraloncology.2024.107128","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"Article 107128"},"PeriodicalIF":4.0,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Submandibular gland transfer into the temporal fossa in patients with oral squamous cell carcinoma: A viable option to prevent radiation-induced xerostomia","authors":"Tan Mai Nguyen ,&nbsp;Pauline Quilhot ,&nbsp;Isabelle Brochériou ,&nbsp;Guillaume Rougier ,&nbsp;Philippe Maingon ,&nbsp;Chloé Bertolus ,&nbsp;Jean-Philippe Foy","doi":"10.1016/j.oraloncology.2024.107125","DOIUrl":"10.1016/j.oraloncology.2024.107125","url":null,"abstract":"<div><div>Oral squamous cell carcinoma (OSCC) is associated with an important mortality and morbidity related to surgery and radiotherapy. In particular, radiation-induced xerostomia has a major impact on patient’s quality of life. Although intensity-modulated radiation therapy allowed mean dose reduction to the spared submandibular gland (SMG) in patients with head and neck squamous cell carcinoma, xerostomia is still an important sequela for patients treated for an OSCC. SMG surgical transfer into anatomical subsite receiving very low radiation doses is a promising approach to prevent xerostomia. Based on a literature review and data from our institutional cohort, we analyzed the oncological safety of SMG preservation. Then, we discussed the feasibility and relevance of SMG transfer into the temporal fossa, in order to prevent radiation-induced xerostomia in patients with OSCC.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"Article 107125"},"PeriodicalIF":4.0,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards improved speech and swallowing outcomes after hemiglossectomy reconstruction: Impact of neurotization and free flap choice","authors":"Eric L. Wu ,&nbsp;Fendi Obuekwe ,&nbsp;Joshua D. Smith ,&nbsp;Mario G. Solari ,&nbsp;Arturo A. Eguia ,&nbsp;Tonge Enoh ,&nbsp;Anthony Tang ,&nbsp;Marci L. Nilsen ,&nbsp;Jonas T. Johnson ,&nbsp;Seungwon Kim ,&nbsp;Kevin J. Contrera ,&nbsp;Shaum S. Sridharan ,&nbsp;Matthew E. Spector","doi":"10.1016/j.oraloncology.2024.107127","DOIUrl":"10.1016/j.oraloncology.2024.107127","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"Article 107127"},"PeriodicalIF":4.0,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142721995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor, “Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.”","authors":"Gnanaprakash Jeyaraj","doi":"10.1016/j.oraloncology.2024.107092","DOIUrl":"10.1016/j.oraloncology.2024.107092","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"Article 107092"},"PeriodicalIF":4.0,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142721996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroid carcinoma in pediatric populations","authors":"Yanan Liu ,&nbsp;Nantao Fu ,&nbsp;Haitao Liu ,&nbsp;Shanshan Su ,&nbsp;Tingting Yang ,&nbsp;Ping Long ,&nbsp;Wei Zhong ,&nbsp;Xiang Min","doi":"10.1016/j.oraloncology.2024.107120","DOIUrl":"10.1016/j.oraloncology.2024.107120","url":null,"abstract":"<div><h3>Objective</h3><div>To analyze the clinicopathological features and predictors of lymph node metastasis (LNM) in the diffuse sclerosing variant of papillary thyroid carcinoma (DSV-PTC) and compare these findings with conventional papillary thyroid carcinoma (C-PTC) in pediatric populations.</div></div><div><h3>Methods</h3><div>Patients aged 18 years or younger who were preoperatively diagnosed with PTC and underwent thyroidectomy at the First Affiliated Hospitals of Nanchang University from January 2017 to May 2024 were included in this study. Demographic and clinicopathological characteristics were retrospectively analyzed. Univariate and multivariate analyses were performed to identify risk factors for lymph node metastasis. Clinical outcomes, including nerve injury, hypocalcemia, and recurrence, were also recorded and evaluated.</div></div><div><h3>Results</h3><div>A total of 119 children were enrolled in this study, with a median age of 15.6 years. Of these, 89 (74.8 %) were female, and 18 (15.1 %) were diagnosed with DSV-PTC. Central lymph node metastasis (CLNM) was observed in 94 (79 %) patients, while 60 (50.4 %) had lateral lymph node metastasis (LLNM). DSV-PTC was associated with a higher incidence of CLNM and LLNM compared to C-PTC (p = 0.039, p &lt; 0.001). Multifocality and bilateral tumors were also more common in DSV-PTC (<em>p</em> &lt; 0.001). Cox regression analysis identified tumor size as an independent predictive factor for CLNM in pediatric C-PTC patients. Tumor size, ETE and the presence of CLNM were independent predictive factors for LLNM. After a mean follow-up of 32.8 months, no patient died from the disease, but four C-PTC patients (4.0 %) developed local recurrences, which were managed surgically. Lung metastasis occurred in 2 (11.1 %)</div><div>DSV-PTC and 1(1.0 %)C-PTC patients, respectively. Permanent injuries included one case of unilateral recurrent laryngeal nerve(RLN) injury and two cases of bilateral RLN injury. Four patients (4.0 %) experienced temporary hypocalcemia, which resolved after 6 months of calcium therapy.</div></div><div><h3>Conclusions</h3><div>DSV-PTC presents unique characteristics of lymph node metastasis and may be more aggressive than conventional PTC in pediatric populations. The presence of CLNM, tumor size and ETE were identified as independent predictors of LLNM in pediatric patients with conventional PTC. Evaluating these prognostic factors may help in customizing individualized surgical approaches for children, thereby reducing unnecessary surgical complications.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"Article 107120"},"PeriodicalIF":4.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142704160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF","authors":"Chang Yan ,&nbsp;Runzhi Wang ,&nbsp;Chaojun Zhang ,&nbsp;Guoxiang Lin ,&nbsp;Youqing Du ,&nbsp;Meiwen Chen ,&nbsp;Fushuang Liu ,&nbsp;Ling Li ,&nbsp;Song Qu ,&nbsp;XiaoDong Zhu","doi":"10.1016/j.oraloncology.2024.107119","DOIUrl":"10.1016/j.oraloncology.2024.107119","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Gemcitabine plus cisplatin (GP) and docetaxel plus cisplatin plus fluorouracil (TPF) are induction chemotherapy (IC) regimens for locally advanced nasopharyngeal carcinoma (LA-NPC). The oral convenience of capecitabine presents its potential as a fluorouracil substitute in the TPF regimen, which has yet to be thoroughly investigated. This study aims to compare the efficacy and safety of the docetaxel, cisplatin, and capecitabine (TPC) with GP and TPF in LA-NPC.</div></div><div><h3>Methods</h3><div>A retrospective analysis was conducted on newly diagnosed stage III-IVa nasopharyngeal carcinoma patients who received GP, TPC, or TPF induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) between February 2019 and December 2021. A comparison of the prognostic outcomes and associated adverse reactions among patients receiving different IC regimens. Multivariate Cox regression was applied to analyze independent prognostic factors, and subgroup survival analyses were conducted based on these factors.</div></div><div><h3>Results</h3><div>A total of 291 LA-NPC patients were included, with 70 receiving TPC, 119 receiving GP, and 102 receiving TPF. Kaplan-Meier survival analysis indicated no significant differences in OS, PFS, LRFS, and DMFS among the 3 groups. Multivariate Cox regression identified T classification and clinical stage as independent prognostic factors. Subgroup analyses revealed no significant differences in OS and PFS between the 3 groups across T1-2 and T3-4 classifications or III and IVa stages.The TPC group exhibited lower incidence rates of treatment-related acute toxicity reactions, including grade 3–4 toxicities.</div></div><div><h3>Conclusion</h3><div>The TPC induction chemotherapy regimen demonstrates comparable efficacy to GP and TPF, while maintaining a favorable safety profile.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"Article 107119"},"PeriodicalIF":4.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142704161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delayed diagnosis to treatment interval (DTI) in head & neck cancers – A systematic review and meta-analysis","authors":"Noémie Villemure-Poliquin ,&nbsp;Rui Fu ,&nbsp;Karolina Gaebe ,&nbsp;Jin Kwon ,&nbsp;Marc Cohen ,&nbsp;Marianne Ruel ,&nbsp;Kennedy Ayoo ,&nbsp;Andrew Bailey ,&nbsp;Madette Galapin ,&nbsp;Julie Hallet ,&nbsp;Antoine Eskander","doi":"10.1016/j.oraloncology.2024.107106","DOIUrl":"10.1016/j.oraloncology.2024.107106","url":null,"abstract":"<div><h3>Introduction</h3><div>Delayed diagnosis to treatment interval (DTI) in head and neck cancers (HNC) can significantly impact patient outcomes. The need for multimodal treatment in HNC may cause delays in initiation of treatment. This systematic review aims to provide a comprehensive understanding of the consequences of delayed DTI on both oncologic and QoL outcomes, proposing a new quality benchmark along the treatment continuum of HNC patients.</div></div><div><h3>Methods</h3><div>We searched MEDLINE, Embase, CENTRAL, Web of Science, and CINAHL databases for trials and cohort studies evaluating the impact of delayed DTI in patients with HNC. Outcomes included overall survival (OS), disease-free survival (DFS), locoregional (LRR) and local recurrences (LR) and distant metastasis.</div></div><div><h3>Results</h3><div>Our search strategy initially identified 10,779 titles and abstracts, of which 63 articles met inclusion criteria for a total of 873,718 patients. The pooled analysis showed that treatment initiation within 30 days improved OS by 9 % compared to longer intervals (aHR: 1.09 [1.06–1.13]; I² = 80 %), with no significant associations found for DFS, LRR, LR, or distant metastasis.</div></div><div><h3>Conclusion</h3><div>While adherence to a 30-day DTI may be associated with improved survival in some HNC patients, significant heterogeneity in the data limits the generalizability of this finding. Further research with more refined analyses, including adjustments for treatment modality and cancer stage, is necessary. Additionally, gaps remain in the literature, particularly in the methodological limitations related to DTI classification.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"160 ","pages":"Article 107106"},"PeriodicalIF":4.0,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}